Login or sign up
For business

Neurophoenix

4.5· 10 reviews
Average ratingExcellent
4.5/ 5

Based on 10 reviews

550%
450%
30%
20%
10%
Ask AI

Questions about Neurophoenix

Based on 10 reviews, listing data and website checks · updated 2 days ago

What is Neurophoenix?

Neurophoenix is a preclinical biotech company based in Paris, Île-de-France, France, advancing a proprietary PTEN inactivation platform to treat optic neuropathies and other neuronal diseases. The business was founded by Monique Lafon, who serves as Chief Scientific Officer, and traces its academic roots to research conducted at Institut Pasteur. They are currently at the preclinical stage of development.

What specific technologies does Neurophoenix use for neuron repair?

The company's core technology relies on two patented, complementary assets: a VHH-based intracellular vectorization platform and a neuroprotective peptide pharmacophore derived from a rabies virus glycoprotein motif. These technologies are designed to deliver therapeutic peptides directly into the cytosol of a neuron, bypassing endosomal degradation. Both assets arose from academic research at Institut Pasteur and are co-owned with that institution.

What patents has Neurophoenix filed and when were they published?

Neurophoenix holds two international patent applications published on December 26, 2025, covering their VHH_NPX vectorization platform and the NVshort neuroprotective peptide. The first patent, WO 2025/262307 A2, describes a single-domain antibody engineered to cross the blood–brain barrier and the plasma membrane. The second, WO 2025/262278 A1, protects a truncated 11–15 amino acid peptide that retains the activity of the original 42-amino-acid sequence.

How does the NVshort peptide differ from the original NVlong sequence?

The NVshort peptide is a truncated version of the parent 42-amino-acid sequence, shortened to 11–15 amino acids without measurable loss of activity. This truncation allows the molecule to be manufactured and fused more efficiently while maintaining its neuroprotective properties. It is specifically designed to address the bottleneck of getting a drug inside the neuron itself.

How does the VHH_NPX vectorization platform achieve direct cytosolic access?

The VHH_NPX scaffold is an unusual single-domain antibody engineered to cross two specific barriers: the blood–brain barrier and the plasma membrane of the neuron. Once inside, it releases its cargo into the cytosol rather than trapping it in the endosomal compartment. This design ensures direct cytosolic access and reduces endosomal degradation of the therapeutic payload.

What is the biological origin of the rabies virus motif used in Neurophoenix's peptide?

The rabies virus glycoprotein motif used in Neurophoenix's pharmacophore was identified by tracing the virus's ability to force neurons to survive. The virus travels along the nervous system by keeping infected cells alive, a mechanism linked to a short motif at the C-terminus of the viral glycoprotein. Neurophoenix isolates this motif to interact with the host scaffolding protein MAST2.

What types of cargo can the Neurophoenix delivery platform transport?

Neurophoenix's platform is designed to deliver peptide cargo and oligonucleotides, such as PMO or ASO, directly into the cytosol of neurons. The technology aims to solve the unmet problem of achieving the highest achievable efficiency in getting a drug inside the neuron itself. This systemic route to CNS targets is critical for treating optic neuropathies and other neuronal diseases.

How do the delivery platform and the pharmacophore work together in Neurophoenix's strategy?

The company's approach is built on a deliberate architecture where the delivery platform and the pharmacophore work together as two halves of the same problem. This pairing ensures that the drug not only enters the neuron efficiently but also remains active once inside. The goal is to unlock neuron repair in conditions where current therapies fail.

Where is Neurophoenix located and what industry does it serve?

Neurophoenix is located in Paris, within the Île-de-France region of France, and operates primarily in the biotechnology industry. The company's website, neurophoenix.fr, is easy to navigate and serves as the central hub for their information. They are focused on advancing their proprietary technology to unlock neuron repair in optic neuropathies.

What themes do multiple reviewers share about their experience with Neurophoenix?

Multiple reviewers on Trustburn highlight the exceptional quality of Neurophoenix's products and their top-notch customer service. Users frequently mention that the company handles inquiries promptly and provides great assistance. The overall sentiment is highly positive, with many customers expressing that they are beyond impressed by the experience.

What features of the website and business model are highlighted by reviewers?

Neurophoenix's website is described as user-friendly and easy to navigate, which contributes to a positive customer experience. The company's assets include a delivery platform and a pharmacophore, both of which are central to their mission. The business aims to provide innovative solutions for neuronal diseases through these specific technological assets.

What specific problem does Neurophoenix's technology aim to solve?

The company's technology is designed to address the specific challenge of intracellular delivery and neuroprotection. By using a VHH-based vectorization platform and a neuroprotective peptide, Neurophoenix targets the cytosol of neurons. This approach is intended to overcome the barriers that typically stop most therapeutics from reaching their target.

What are the specific details of the two international patent applications?

Neurophoenix's two international patent applications, published on December 26, 2025, cover the VHH_NPX vectorization platform and the NVshort neuroprotective peptide. These patents are co-owned with Institut Pasteur and were filed as a deliberate architecture. The platform patent claims the VHH_NPX scaffold, while the composition of matter patent covers the truncated pharmacophore.

How is Neurophoenix rated on Trustburn?

On Trustburn, Neurophoenix has a rating of 4.5 out of 5 based on 10 reviews.

Is Neurophoenix on social media?

Neurophoenix has official profiles on Linkedin.

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Neurophoenix

Neurophoenix is a preclinical stage biotech company advancing its proprietary PTEN inactivation platform to unlock neuron repair in optic neuropathies and several other neuronal diseases

Categories
Biotechnology